Shionogi expecting sharp uptick in 2Q profit
This article was originally published in Scrip
Shionogi is preparing to report a big increase in profit well ahead of its own projections for the fiscal first half ended 30 September, boosted by currency effects and several other positive factors.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.